Background and purpose
======================

Akt-1 is a serine/threonine-protein kinase that regulates growth factor-dependent cell proliferation and survival. Activated-Akt-1 causes Bcl-2 release from the BAD:Bcl-2 inactive complex. Bcl-2 is not only able to prevent apoptosis, as a downstream effector of Akt-1, but also can delay cell-cycle progression. Akt-1 is over-expressed in breast cancer cell lines and tumours, while Bcl-2 has been related with tumour survival and drug resistance *in vitro* and to an ER+/well differentiated sub-group of tumours, *in vivo*. Since endocrine treatment effectiveness could be due to activation of the apoptotic program, we wanted to investigate the expression and relationship between these factors as well as other variables (C-erbB-2, ER, and S-phase).

Patients and methods
====================

Frozen tissue from primary tumours of 104 breast cancer patients (age \<50 years), who received tamoxifen, zoladex or both (follow-up period \>10 years), was used to determine the expression of Bcl-2 and Akt-1 by immunohistochemistry. C-erbB-2 expression and S-phase were analysed using flow cytometry. The statistical analysis was performed using the \'Statistica\' package.

Results
=======

There was a positive correlation between Bcl-2 and Akt-1 expression (38 Akt-1+/65 Bcl-2+ compared with 11 Akt-1+/37 Bcl-2- cases, *P* = 0.007). This correlation also appears in metastasis-free patients (*P* = 0.0008) but not in those patients with metastasis (*P* = 1.0). Bcl-2 alone was not significantly associated with ER, S-phase or c-erbB-2 expression (*P* \> 0.05) but a trend was observed for Bcl-2-positive cases to present ER+/low-S-phase/C-erbB-2-negative phenotypes. In terms of distant-recurrence-free survival, those patients expressing Akt-1+/ Bcl-2+ survived longer than Akt-1+/Bcl-2- patients (*P* = 0.028) while no benefit was observed for Bcl-2 (*P* = 0.6) or Akt-1 (*P* = 0.9) individually.

Conclusions
===========

The results suggest that Akt-1 might reinforce the prognostic value of Bcl-2, and probably this phenotype characterises a subgroup of patients less prone to undergo metastasis.
